Cell cycle inhibition preserves endothelial function in genetically engineered rabbit vein grafts

Area of Science:

• Vascular Biology
• Gene Therapy
• Cardiovascular Research

Background:

• Endothelial dysfunction is a key factor in vascular diseases like atherosclerosis.
• Autologous vein grafts are prone to neointimal hyperplasia and atherosclerosis.
• Gene therapy offers a potential strategy to modify graft behavior.

Purpose of the Study:

• To investigate the impact of gene therapy on endothelial function in vein grafts.
• To determine if preserving endothelial function protects against graft atherosclerosis.
• To explore the relationship between cell cycle arrest and endothelial phenotype.

Main Methods:

• Ex vivo gene therapy of rabbit vein grafts using antisense oligodeoxynucleotides (AS ODN).
• Transfection with AS ODN targeting proliferating cell nuclear antigen (PCNA) and cell division cycle 2 (cdc2) kinase.
• Assessment of nitric oxide production, vasorelaxation, superoxide radical generation, VCAM-1 expression, and monocyte binding.

Main Results:

• AS ODN treatment significantly increased nitric oxide elaboration and vasorelaxation.
• Preserved endothelial function was linked to reduced superoxide generation and VCAM-1 expression.
• Gene-modified grafts showed reduced monocyte binding and resistance to atherosclerosis.
• These effects were observed in both normal and hypercholesterolemic rabbits.

Conclusions:

• Arresting vascular cell cycle progression via AS ODN preserves normal endothelial phenotype and function.
• This genetic engineering strategy reduces susceptibility to occlusive vascular disease.
• AS ODN therapy represents a promising approach for preventing vein graft atherosclerosis and dysfunction.